{
    "root": "e26cdb06-a79d-44f0-a4c2-a0cc4e35ca87",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "cisatracurium besylate",
    "value": "20241031",
    "ingredients": [
        {
            "name": "CISATRACURIUM BESYLATE",
            "code": "80YS8O1MBS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3721"
        },
        {
            "name": "BENZENESULFONIC ACID",
            "code": "685928Z18A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64455"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "cisatracurium besylate injection indicated : \u2022as adjunct general anesthesia facilitate tracheal intubation adults pediatric patients 1 month 12 years age \u2022to provide skeletal muscle relaxation adults surgical procedures mechanical ventilation icu \u2022to provide skeletal muscle relaxation surgical procedures via infusion pediatric patients 2 years older . limitations cisatracurium besylate injection recommended rapid sequence endotracheal intubation due time required onset action .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "store cisatracurium besylate injection cap ferrule intact manner minimizes possibility selecting wrong product ( 2.1 ) \u2022 administer intravenously supervision experienced clinicians familiar \u2019 actions possible complications ( 2.1 ) \u2022 personnel facilities resuscitation life support , cisatracurium besylate antagonist immediately available ( 2.1 ) \u2022 peripheral nerve stimulator determine adequacy blockade ( e.g . , need additional doses ) , minimize risk overdosage underdosage , assess extent recovery blockade , potentially limit exposure toxic metabolites dose titration , facilitate rapid reversal cisatracurium besylate-induced paralysis ( 2.1 ) \u2022 full prescribing information : instructions adults , pediatric patients , geriatric patients , patients neuromuscular disease , burns , end- stage renal disease , patients undergoing coronary artery bypass graft surgery induced hypothermia ( 2.2 , 2.3 , 2.4 , 2.5 ) continuous infusion rates ( 2.6 ) preparation instructions ( 2.7 ) compatibility ( 2.8 )",
        "doid_entities": [
            {
                "text": "neuromuscular disease (DOID:440)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_440"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cisatracurium besylate injection , usp clear , colorless pale yellow greenish colored solution supplied follows : strength ( mg cisatracurium ) container size ndc 10 mg/5 ml ( 2 mg/ml ) 5 ml single-dose vial pack 10 's 0781-3150-95 200 mg/20 ml ( 10 mg/ml ) 20 ml single-dose vial pack 10 's 0781-3153-95 discard unused portion . storage refrigerate cisatracurium besylate injection , usp 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) carton preserve potency . protect light . freeze . upon removal unused vial refrigeration room temperature storage conditions ( 25\u00b0c/77\u00b0f ) , cisatracurium besylate injection , usp within 21 days , even re-refrigerated .",
    "adverseReactions": "\u2022cisatracurium besylate injection contraindicated patients known hypersensitivity cisatracurium . severe anaphylactic cisatracurium besylate reported [ ( 5.4 ) ] .",
    "indications_original": "Cisatracurium besylate injection is indicated:\n                  \n                     \n                        \u2022as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age\n                     \n                        \u2022to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU\n                     \n                        \u2022to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older. \n                  \n                  \n                     Limitations of Use\n                  \n                  Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action.",
    "contraindications_original": "Store cisatracurium besylate injection with the cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product (2.1) \u2022 Administer intravenously only by or under the supervision of experienced clinicians familiar with drug\u2019s actions and possible complications ( 2.1 ) \u2022 Use only if personnel and facilities for resuscitation and life support, and a cisatracurium besylate antagonist are immediately available ( 2.1 ) \u2022 Use a peripheral nerve stimulator to determine adequacy of blockade (e.g., need for additional doses), minimize risk of overdosage or underdosage, assess extent of recovery from blockade, potentially limit exposure to toxic metabolites through dose titration, and facilitate more rapid reversal of cisatracurium besylate-induced paralysis ( 2.1 ) \u2022 See the Full Prescribing Information for: o Dosage and administration instructions in adults, pediatric patients, geriatric patients, patients with neuromuscular disease, burns, end- stage renal disease, and patients undergoing coronary artery bypass graft surgery with induced hypothermia ( 2.2 , 2.3, 2.4, 2.5 ) o Continuous infusion rates ( 2.6 ) o Preparation instructions ( 2.7 ) o Drug compatibility ( 2.8 )",
    "warningsAndPrecautions_original": "Cisatracurium besylate injection, USP is a clear, colorless to pale yellow or greenish colored solution supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                              \n                                 (mg of Cisatracurium)\n                              \n                           \n                           \n                              \n                                 Container\n                              \n                           \n                           \n                              \n                                 Size\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              10 mg/5 mL\n                              (2 mg/mL)\n                           \n                           \n                              5 mL Single-Dose Vial\n                           \n                           \n                              Pack of 10's\n                           \n                           \n                              0781-3150-95\n                           \n                        \n                        \n                           \n                              200 mg/20 mL\n                              (10 mg/mL)\n                           \n                           \n                              20 mL Single-Dose Vial\n                           \n                           \n                              Pack of 10's\n                           \n                           \n                              0781-3153-95\n                           \n                        \n                     \n                  \n                  Discard Unused Portion.\n                  \n                     Storage\n                  \n                  Refrigerate cisatracurium besylate injection, USP at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the carton to preserve potency. Protect from light. DO NOT FREEZE. Upon removal of the unused vial from refrigeration to room temperature storage conditions (25\u00b0C/77\u00b0F), use cisatracurium besylate injection,USP within 21 days, even if re-refrigerated.",
    "adverseReactions_original": "\u2022Cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. Severe anaphylactic reactions to cisatracurium besylate have been reported [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "cisatracurium besylate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3721"
        }
    ]
}